Markku Jalkanen
Markku Jalkanen is a Finnish biochemist and entrepreneur, best known for his contributions to the field of pharmacology and his role as the CEO of Faron Pharmaceuticals Ltd.
Early Life and Education[edit | edit source]
Markku Jalkanen was born in Finland. He completed his undergraduate studies in biochemistry at the University of Helsinki, where he also earned his Ph.D. in biochemistry. His doctoral research focused on the role of certain proteins in the immune system.
Career[edit | edit source]
After completing his Ph.D., Jalkanen continued his research in the field of biochemistry and immunology, with a particular focus on the development of new therapeutic strategies for inflammatory diseases and cancer. His research has led to the discovery of several novel drug candidates, some of which are currently in clinical trials.
In 2003, Jalkanen co-founded Faron Pharmaceuticals Ltd, a biopharmaceutical company focused on the development of novel treatments for life-threatening medical conditions. As the CEO of the company, he has overseen the development and clinical testing of several innovative drug candidates.
Contributions to Pharmacology[edit | edit source]
Jalkanen's research has significantly advanced our understanding of the immune system and has led to the development of several promising drug candidates. His work has focused on the role of certain proteins in the immune response, and how these proteins can be targeted to treat various diseases.
One of his most significant contributions to the field of pharmacology is the development of Clevegen, a novel drug candidate for the treatment of cancer. Clevegen works by modulating the immune system to enhance the body's natural ability to fight cancer.
Recognition[edit | edit source]
Jalkanen's contributions to the field of pharmacology have been recognized with several awards and honors. He is a member of the Finnish Academy of Science and Letters and has received the Finnish Biochemical Society's Award for Excellence in Biochemical Research.
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
